Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 11 01:05PM ET
27.74
Dollar change
-0.09
Percentage change
-0.33
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y11.62% Shs Outstand Perf Week-1.51%
SponsorFirst Trust ETF Type Tagsequity Return% 3Y4.20% Total Holdings51 Perf Month-4.65%
Fund Family Bond Type Tagspharmaceutical Return% 5Y5.63% AUM15.32M Perf Quarter-4.31%
IndexNasdaq US Smart Pharmaceuticals Index Average Maturity Tagsgrowth Return% 10Y NAV% Perf Half Y2.07%
Index Weighting Commodity Type Tagsvalue Return% SI NAV/sh Perf Year8.71%
Active/Passive Quant Type Tagsvolatility Flows% 1M-8.50% 52W Range25.42 - 29.72 Perf YTD4.23%
Dividend TTM0.44 (1.59%) ESG Type Tags- Flows% 3M-8.50% 52W High-6.66% Beta0.65
Dividend Ex-DateSep 26, 2024 Dividend Type Sector/Theme Flows% YTD-21.54% 52W Low9.13% ATR (14)0.22
Expense0.60% Structure Type Region Flows% 1Y RSI (14)40.64 Volatility0.40% 0.64%
Option/ShortYes / No Growth/Value Dev/Emerg Flows% 3Y Rel Volume1.37 Prev Close27.83
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume2.96K Price27.74
SMA20-0.75% SMA50-1.95% SMA200-0.44% Trades Volume2,378 Change-0.33%
Nov-11-20 08:00AM
Feb-07-20 11:05AM
Nov-06-19 11:00AM
Sep-24-19 05:27PM
Aug-07-19 10:59AM
10:05AM Loading…
May-09-19 10:05AM
Mar-01-19 08:00AM
Feb-28-19 04:43PM
Feb-07-19 11:15AM
Jan-23-19 02:04PM
Oct-24-18 11:59AM
Oct-12-18 06:00AM
Jan-26-18 09:02AM
Jan-12-18 07:31AM
Jan-01-18 07:33AM
10:36AM Loading…
Sep-12-17 10:36AM
Sep-04-17 09:06AM
Sep-01-17 07:38AM
Aug-30-17 09:07AM
Aug-11-17 03:59PM
May-05-17 09:59AM
Mar-22-17 05:25PM
Dec-09-16 09:36AM
Oct-25-16 03:04PM
Oct-20-16 08:07AM
Oct-14-16 12:04PM
Sep-28-16 09:00AM
Sep-27-16 09:00AM
Sep-22-16 01:55PM
Sep-21-16 09:12AM
First Trust Nasdaq Pharmaceuticals ETF seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals IndexTM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.